Analyst group Stifel Nicolaus has said that Dr Pepper Snapple Group may get a lower windfall than first assumed from The Coca-Cola Co’s deal to buy the North American operations of Coca-Cola Enterprises.

Dr Pepper Snapple (DPS) may only get US$500m from the Coca-Cola deal, compared to the $800m previously anticipated, said Stifel Nicolaus today (12 May).

DPS is set to get the payment as certain bottling contracts pass from Coca-Cola Enterprises to Coca-Cola Co. It has already received a $900m payment from PepsiCo, reflecting PepsiCo gaining the licences to certain DPS brands following its deal to acquire Pepsi Bottling Group and PepsiAmericas.

Stifel has reduced its estimate due to Coca-Cola’s stronger weighting towards the fountain drinks channel, rather than packaged drinks.     

“Coke has an approximate 70% share of the US fountain market, consisting of chain and other accounts such as Burger King where soda is fountain-dispensed,” said Stifel. “This may mean a lesser change-of-control cash payment.”

However, despite a lower than expected payment from the Coca-Cola CCE deal, Stifel said that DPS may improve value in the longer term due to greater access to the Coke fountain system.

Many analysts toasted last week’s first quarter results for DPS and have tipped the company for growth in 2010.

Stay informed for just £1! *

Subscribe to Just Drinks for unbiased coverage of the global drinks industry, offering insights into the corporate strategies of beverage manufacturers and brands worldwide.


What’s included in your subscription:
  • Unlimited access to Just Drinks content including daily global news, in-depth analysis, and interviews with C-suite executives
  • Unbeatable coverage of categories from beer, wine and spirits to soft drinks and hot beverages
  • Unrivalled drinks industry comment from leading sector specialists

Ready to stay informed? Subscribe now and gain access to exclusive content.

Subscribe

Have a subscription? Sign in

For further details on subscribing, click here. Need multi-user access? Explore our corporate subscriptions now.

*After your 1-month trial, your subscription will continue at £315 per year.